Mechanisms of disease: Inflammatory mediators and cancer prevention (Q36303978)

13 August 2017

1 reference

title

Mechanisms of disease: Inflammatory mediators and cancer prevention (English)

1 reference

13 August 2017

0 references

Jason R Mann

1

1 reference

13 August 2017

Michael G Backlund

series ordinal

2

1 reference

13 August 2017

Raymond N DuBois

series ordinal

3

1 reference

13 August 2017

1 April 2005

1 reference

Nature Clinical Practice Oncology

13 August 2017

1 reference

13 August 2017

2

1 reference

13 August 2017

4

1 reference

13 August 2017

202-210

1 reference

https://scigraph.springernature.com/pub.10.1038/ncponc0140

13 August 2017

0 references

cites work

Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

DNA content as a prognostic marker in patients with oral leukoplakia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

COX-2: a target for colon cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

A randomized trial of aspirin to prevent colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Primary chemoprevention of familial adenomatous polyposis with sulindac

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Cyclooxygenase-2: a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Enhancement of colon carcinogenesis by prostaglandin E2 administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

Chemoprevention of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Colorectal cancer and nonsteroidal anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Aspirin use and reduced risk of fatal colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Sulindac causes regression of rectal polyps in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Combinatorial chemoprevention of intestinal neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Low-dose aspirin and incidence of colorectal tumors in a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Effect of sulindac on sporadic colonic polyps.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0140

7 January 2021

Identifiers

DOI

10.1038/NCPONC0140

1 reference

Dimensions Publication ID

13 August 2017

1048988755

0 references

Fatcat ID

release_yzwxkmjnuvd2hmyyqh2sa2tmni

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yzwxkmjnuvd2hmyyqh2sa2tmni

24 November 2022

mapped directly with Wikidata item

1 reference